Evidence map›Paper›PMID 35917826›Full record

ArticleRoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin2022

Design and Rationale of the HANSE Study: A Holistic German Lung Cancer Screening Trial Using Low-Dose Computed Tomography.

Jens Vogel-Claussen, Florian Lasch, Benjamin-Alexander Bollmann, Katharina May, Alexander Kuhlmann, Gerald Schmid-Bindert, Rudolf Kaaks, Jörg Barkhausen, Sabine Bohnet, Martin Reck

Open access · hybridAbstract read
In one paragraph

Article in RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Incidental Pulmonary Nodules: What Should We Do in 2026?Respiration; international review of thoracic diseases · 2026
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Jens Vogel-ClaussenDepartment of Diagnostic and Interventional Radiology, Hannover Medical School, Hannover, Germany.ORCID 0000-0001-5595-6948
Florian LaschDepartment of Biostatistics, Hannover Medical School, Hannover, Germany.
Benjamin-Alexander BollmannDepartment of respiratory medicine, Hannover Medical School, Hannover, Germany.
Katharina MayDepartment of Radiology and Nuclear Medicine, University Medical Center Schleswig-Holstein Campus Lübeck, Lübeck, Germany.
Alexander KuhlmannWorking Group Health Economics, Martin Luther University Halle Wittenberg, Halle, Germany.
Gerald Schmid-BindertOncology Medical Department, AstraZeneca GmbH, Hamburg, Germany.
Rudolf KaaksTranslational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research, Giessen, Germany.
Jörg BarkhausenDepartment of Radiology and Nuclear Medicine, University Medical Center Schleswig-Holstein Campus Lübeck, Lübeck, Germany.
Sabine BohnetDepartment of Pulmonology, University Medical Center Schleswig Holstein Campus Lübeck, Lübeck, Germany.
Martin ReckDepartment of Thoracic Oncology, LungenClinic Grosshansdorf GmbH, Grosshansdorf, Germany.
German Center for Lung Research · DEMedizinische Hochschule Hannover · DEGerman Cancer Research Center · DEHeidelberg University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the high prevalence and mortality of lung cancer and proven effectiveness of low-dose computed tomography (LDCT) to reduce mortality, Germany still lacks a national screening program. The German Institute for Quality and Efficiency in Health Care (IQWiG) and the Federal Office for Radiation Protection (BfS) both published positive scientific evaluations recommending a quality-controlled national screening program. IQWiG underlined the importance of a clear risk definition, integrated smoking cessation programs, and quality assurance, highlighting the necessity of procedural optimization.In the HANSE study, former and current smokers aged 55-79 years are assessed for their lung cancer risk by the NELSON and PLCO

Indexed as

Lung NeoplasmsPulmonary EmphysemaCalciumEarly Detection of CancerHumansMass ScreeningTomography, X-Ray ComputedCalcium

Identifiers

PMID35917826
PMCPMC9708322
OpenAlexW4289523605

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.